Pharma Deals
-
{
- All
- News
-
Indian Pharmaceutical Body Signs 3 Memorandums To Strengthen Drug Safety And Quality Standards
The Indian Pharmacopoeia Commission has signed memoranda with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services to strengthen drug safety, quality assurance and pharmacovigilance.
-
Indian Pharmaceutical Body Signs 3 Memorandums To Strengthen Drug Safety And Quality Standards
The Indian Pharmacopoeia Commission has signed memoranda with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services to strengthen drug safety, quality assurance and pharmacovigilance.
-
Sun Pharma-Ranbaxy Deal Gets BSE, NSE Clearance
The 'no-objection' from the two exchanges would allow the two companies to file with the High Court for further clearance of the deal and marks one of the numerous regulatory approvals that Sun they need to consummate the transaction.
-
High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover
The court last month ordered an "interim status quo" on the deal, pending a decision on a petition for a probe into alleged insider trading.
-
Cipla Medpro To Acquire Stake In Brandmed
Cipla will use the acquisition to deliver holistic care to non-communicable disease patients.
-
Sun Pharma Arm To Commence Distribution Of Formulation Products In India
This phased transition is expected to be fully completed by the first quarter of 2019-20.
-
Eris Lifesciences Buys Strides Shasun’s India Business For Rs 500 crore
Rs 500 crore deal to help Eris Lifesciences strengthen its position in the CNS (Central Nervous System) segment.
-
Eris Lifesciences Buys Strides Shasun’s India Business For Rs 500 crore
Rs 500 crore deal to help Eris Lifesciences strengthen its position in the CNS (Central Nervous System) segment.
-
Fosun Agrees To Buy KKR-Backed Gland Pharma For $1.4 Billion: Report
Shanghai Fosun Pharmaceutical Group Co Ltd has agreed to buy Gland Pharma - backed by KKR & Co LP - for about $1.4 billion, a person with direct knowledge of the matter said, in India's largest inbound acquisition this year.
-
China's Fosun To Sign Agreement For $1.4 Billion Gland Pharma Buy: Report
Shanghai Fosun Pharmaceutical (Group) Co will sign a definitive agreement on Wednesday to buy a controlling stake in India's Gland Pharma in a $1.4 billion deal, the Economic Times newspaper reported, citing a source with direct knowledge.
-
India Among Top 10 Acquirers in US Market This Year: Report
India has been ranked among top 10 acquirers in the US market this year with 16 deals valued at $1.7 billion, according to a report by Baker & McKenzie.
-
Sun Pharma-Ranbaxy Deal Gets BSE, NSE Clearance
The 'no-objection' from the two exchanges would allow the two companies to file with the High Court for further clearance of the deal and marks one of the numerous regulatory approvals that Sun they need to consummate the transaction.
-
High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover
The court last month ordered an "interim status quo" on the deal, pending a decision on a petition for a probe into alleged insider trading.
-
Indian Pharmaceutical Body Signs 3 Memorandums To Strengthen Drug Safety And Quality Standards
The Indian Pharmacopoeia Commission has signed memoranda with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services to strengthen drug safety, quality assurance and pharmacovigilance.
-
Indian Pharmaceutical Body Signs 3 Memorandums To Strengthen Drug Safety And Quality Standards
The Indian Pharmacopoeia Commission has signed memoranda with the Goa State Pharmacy Council, Quality Council of India, and HLL Infra Tech Services to strengthen drug safety, quality assurance and pharmacovigilance.
-
Sun Pharma-Ranbaxy Deal Gets BSE, NSE Clearance
The 'no-objection' from the two exchanges would allow the two companies to file with the High Court for further clearance of the deal and marks one of the numerous regulatory approvals that Sun they need to consummate the transaction.
-
High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover
The court last month ordered an "interim status quo" on the deal, pending a decision on a petition for a probe into alleged insider trading.
-
Cipla Medpro To Acquire Stake In Brandmed
Cipla will use the acquisition to deliver holistic care to non-communicable disease patients.
-
Sun Pharma Arm To Commence Distribution Of Formulation Products In India
This phased transition is expected to be fully completed by the first quarter of 2019-20.
-
Eris Lifesciences Buys Strides Shasun’s India Business For Rs 500 crore
Rs 500 crore deal to help Eris Lifesciences strengthen its position in the CNS (Central Nervous System) segment.
-
Eris Lifesciences Buys Strides Shasun’s India Business For Rs 500 crore
Rs 500 crore deal to help Eris Lifesciences strengthen its position in the CNS (Central Nervous System) segment.
-
Fosun Agrees To Buy KKR-Backed Gland Pharma For $1.4 Billion: Report
Shanghai Fosun Pharmaceutical Group Co Ltd has agreed to buy Gland Pharma - backed by KKR & Co LP - for about $1.4 billion, a person with direct knowledge of the matter said, in India's largest inbound acquisition this year.
-
China's Fosun To Sign Agreement For $1.4 Billion Gland Pharma Buy: Report
Shanghai Fosun Pharmaceutical (Group) Co will sign a definitive agreement on Wednesday to buy a controlling stake in India's Gland Pharma in a $1.4 billion deal, the Economic Times newspaper reported, citing a source with direct knowledge.
-
India Among Top 10 Acquirers in US Market This Year: Report
India has been ranked among top 10 acquirers in the US market this year with 16 deals valued at $1.7 billion, according to a report by Baker & McKenzie.
-
Sun Pharma-Ranbaxy Deal Gets BSE, NSE Clearance
The 'no-objection' from the two exchanges would allow the two companies to file with the High Court for further clearance of the deal and marks one of the numerous regulatory approvals that Sun they need to consummate the transaction.
-
High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover
The court last month ordered an "interim status quo" on the deal, pending a decision on a petition for a probe into alleged insider trading.
